The Stop Patient Abuse Now (SPAN) Coalition has announced that theseniors' activist association, the Gray Panthers, has filed a class-action lawsuit against Bristol-Myers Squibb for the damages which it claims the company has caused by delaying competition to its anti-anxiety drug BuSpar (buspirone: Marketletter April 16).
Lawsuits have also been filed against the company on behalf of the HIP Health Plan of Florida and Richard Levine, a buspirone user in Florida.
According to SPAN, the lawsuit is part of the coalition's new strategy to stop what it describes as abusive practices by drug companies that prevent competition. "Consumers are tired of waiting for Congress," stated Tim Fuller, who is SPAN's founder and executive director of the Gray Panthers. "We're taking matters into our own hands now, and we're not stopping until we get reform."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze